NASDAQ:ICPT - Intercept Pharmaceuticals Price Target & Analyst Ratings

Sign in or create an account to add this stock to your watchlist.
$106.74 +1.52 (+1.44 %)
(As of 12/19/2018 04:12 AM ET)
Previous Close$105.22
Today's Range$105.58 - $109.97
52-Week Range$51.05 - $133.74
Volume363,900 shs
Average Volume647,286 shs
Market Capitalization$3.20 billion
P/E Ratio-7.42
Dividend YieldN/A
Beta-1.03

Analyst Ratings

Intercept Pharmaceuticals (NASDAQ:ICPT) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
19 Wall Street analysts have issued ratings and price targets for Intercept Pharmaceuticals in the last 12 months. Their average twelve-month price target is $150.6875, suggesting that the stock has a possible upside of 41.17%. The high price target for ICPT is $253.00 and the low price target for ICPT is $57.00. There are currently 5 hold ratings and 14 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyHoldHold
Consensus Rating Score: 2.742.682.432.33
Ratings Breakdown: 0 Sell Rating(s)
5 Hold Rating(s)
14 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
6 Hold Rating(s)
13 Buy Rating(s)
0 Strong Buy Rating(s)
2 Sell Rating(s)
10 Hold Rating(s)
10 Buy Rating(s)
1 Strong Buy Rating(s)
3 Sell Rating(s)
8 Hold Rating(s)
10 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $150.6875$144.75$127.9524$124.4737
Price Target Upside: 41.17% upside40.94% upside10.34% upside74.35% upside

Intercept Pharmaceuticals (NASDAQ:ICPT) Consensus Price Target History

Price Target History for Intercept Pharmaceuticals (NASDAQ:ICPT)

Intercept Pharmaceuticals (NASDAQ:ICPT) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
12/11/2018B. RileyInitiated CoverageBuy ➝ Buy$155.00 ➝ $155.00HighView Rating Details
12/6/2018Cantor FitzgeraldReiterated RatingBuy$170.00LowView Rating Details
11/19/2018CIBCUpgradeMarket Perform ➝ OutperformMediumView Rating Details
11/19/2018OppenheimerUpgradeMarket Perform ➝ Outperform$140.00MediumView Rating Details
11/19/2018UBS GroupUpgradeMarket Perform ➝ OutperformMediumView Rating Details
11/6/2018WedbushSet Price TargetBuy$220.00HighView Rating Details
10/31/2018Needham & Company LLCReiterated RatingHoldHighView Rating Details
10/2/2018Raymond JamesDowngradeStrong-Buy ➝ Outperform$126.00 ➝ $141.00HighView Rating Details
9/12/2018Roth CapitalInitiated CoverageBuy ➝ Buy$192.00LowView Rating Details
8/15/2018Royal Bank of CanadaDowngradeOutperform ➝ Sector Perform$244.00HighView Rating Details
8/6/2018Goldman Sachs GroupUpgradeSell ➝ Buy$46.00 ➝ $157.00HighView Rating Details
8/3/2018LaidlawDowngradeBuy ➝ Hold$90.00 ➝ $95.00MediumView Rating Details
5/9/2018CowenReiterated RatingBuy$88.00LowView Rating Details
2/15/2018BMO Capital MarketsBoost Price TargetOutperform ➝ Outperform$152.00 ➝ $155.00HighView Rating Details
2/13/2018Wells Fargo & CoReiterated RatingMarket Perform$62.00 ➝ $57.00MediumView Rating Details
2/12/2018Deutsche BankInitiated CoverageBuy$103.00MediumView Rating Details
1/25/2018Robert W. BairdReiterated RatingOutperform$332.00 ➝ $253.00LowView Rating Details
1/22/2018Credit Suisse GroupSet Price TargetBuy$201.00 ➝ $167.00HighView Rating Details
12/29/2017CitigroupSet Price TargetHold$74.00HighView Rating Details
11/28/2017Leerink SwannReiterated RatingHold$60.00LowView Rating Details
10/13/2017Bank of AmericaLower Price TargetUnderperform$102.00 ➝ $73.00N/AView Rating Details
10/6/2017Seaport Global SecuritiesReiterated RatingBuy$136.00N/AView Rating Details
10/4/2017JMP SecuritiesDowngradeOutperform ➝ Market PerformHighView Rating Details
9/26/2017Jefferies Financial GroupReiterated RatingBuy$275.00 ➝ $135.00LowView Rating Details
9/22/2017Morgan StanleyReiterated RatingUnderweight$75.00 ➝ $50.00HighView Rating Details
2/16/2017FBR & CoReiterated RatingMarket Perform$200.00N/AView Rating Details
(Data available from 12/19/2016 forward)
This page was last updated on 12/19/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel